Anne Thomas
YOU?
Author Swipe
View article: Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1 Open
Background Neutralization of interferon (IFN)-γ abrogates the efficacy of anti-programmed death-ligand 1 (PD-(L)1) checkpoint inhibitors. Most epithelial cells do not constitutively express major histocompatibility complex (MHC) class II b…
OS03.6.A POSTSURGICAL ISCHEMIA FOSTERS TUMOR CELL PLASTICITY IN RESIDUAL GLIOBLASTOMA Open
BACKGROUND Glioblastoma (GBM), the most lethal primary brain tumor, has a dismal prognosis, with a median survival of only 8 months and a 5-year survival rate of only 6.9%. Despite extensive research, the mechanisms underlying GBM resistan…
View article: Learning to estimate sample-specific transcriptional networks for 7,000 tumors
Learning to estimate sample-specific transcriptional networks for 7,000 tumors Open
Cancers are shaped by somatic mutations, microenvironment, and patient background, each altering gene expression and regulation in complex ways, resulting in heterogeneous cellular states and dynamics. Inferring gene regulatory networks (G…
View article: Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February 2025 Open
Maternal respiratory syncytial virus (RSV) vaccine and nirsevimab, a long-acting monoclonal antibody for infants aged 0-7 months and children aged 8-19 months who are at increased risk for severe RSV disease, became widely available for pr…
View article: Invasive Group A Streptococcal Infections in 10 US States
Invasive Group A Streptococcal Infections in 10 US States Open
Importance Invasive group A Streptococcus (GAS) infections are associated with substantial morbidity, mortality, and economic burden. Objective To update trends in invasive GAS disease incidence rates in 10 US states between 2013 and 2022.…
View article: Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance Open
Genomic sequencing of tumours improves patient outcomes through implementation of precision oncology. At present, genomic testing is mainly confined to research settings, with samples sent to biopharmaceutical companies for analysis. The e…
View article: 419. Changing Epidemiology of Pediatric Invasive Group A <i>Streptococcus</i> Infections in the United States, 2004-2022
419. Changing Epidemiology of Pediatric Invasive Group A <i>Streptococcus</i> Infections in the United States, 2004-2022 Open
Background Recent reports from children’s hospitals of increasing pediatric invasive Group A Streptococcus (iGAS) infections triggered national concern. Clindamycin and penicillin dual therapy is often recommended for iGAS, which is life-t…
View article: P-715. Chronic Conditions as Risk Factors for Respiratory Syncytial Virus-Associated Hospitalization among Community-Dwelling Adults Aged ≥50 Years, 2017 to 2018
P-715. Chronic Conditions as Risk Factors for Respiratory Syncytial Virus-Associated Hospitalization among Community-Dwelling Adults Aged ≥50 Years, 2017 to 2018 Open
Background In 2023, CDC recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥ 60 years using shared clinical decision-making. Clinical trials of RSV vaccines in younger age groups are ongoing. Identifying chronic cond…
View article: Multi-indication Evidence Synthesis in Oncology Health Technology Assessment: Meta-analysis Methods and Their Application to a Case Study of Bevacizumab
Multi-indication Evidence Synthesis in Oncology Health Technology Assessment: Meta-analysis Methods and Their Application to a Case Study of Bevacizumab Open
Background Multi-indication cancer drugs receive licensing extensions to include additional indications, as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the…
An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy Open
Breast Cancer is the most common cancer among women globally. Despite significant improvements in overall survival, many tumours are refractory to therapy and so novel approaches are required to improve patient outcomes. We have evaluated …
Clear cell adenocarcinoma of the cervix and its mimickers - A series of 19 cases from a tertiary care referral centre in India Open
Clear cell adenocarcinoma (CCAC) of cervix is a rare subtype of endocervical adenocarcinoma that accounts for 4% of all cervical adenocarcinoma with many morphological mimickers. Retrospectively study cases of cervical clear cell adenocarc…
View article: The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology
The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology Open
Background Translating research, achieving impact, and assessing impact are important aspirations for all research collaboratives but can prove challenging. The Hunter Cancer Research Alliance (HCRA) was funded from 2014 to 2021 to enhance…
View article: Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT Open
Background Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. Objectives To e…
P12.01 Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes Open
Background Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has greatly improved treatment options for patients with recurrent/metastatic (R/M) melanoma. With current treatment options, complete response (CR) does not…
View article: Multi-indication evidence synthesis in oncology health technology assessment
Multi-indication evidence synthesis in oncology health technology assessment Open
Background: Cancer drugs receive licensing extensions to include additional indications as trial evidence on treatment effectiveness accumulates. We investigate how sharing information across indications can strengthen the inferences suppo…
Comprehensive dialectical behavior therapy for adolescents in a juvenile correctional treatment center: a pilot evaluation Open
Background Incarcerated youth commonly present with emotion dysregulation, aggression, and comorbid psychiatric disorders, yet often do not receive necessary mental health treatment while confined. It is therefore crucial to expand the evi…
Dialectical Behavior Therapy in Juvenile Correctional and Detention Facilities: A Scoping Review Open
Dialectical behavior therapy (DBT) has shown preliminary success in the treatment of youth in forensic settings. However, the implementation of DBT varies considerably from facility to facility. A scoping review was conducted to detail DBT…
Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy. Open
8511 Background: AXL receptor tyrosine kinase is a key facilitator of immune escape and drug resistance, conferring a more aggressive phenotype. Targeting the PD1-PDL1 axis has demonstrated significant efficacy in patients with relapsed ma…
Supplementary Figure 4 from High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial Open
Results of parallel siRNA screens in FGFR driven cell lines with analysis of ERK and AKT phosphorylation in and panel of FGFR driven cancer cell lines.
Supplementary Figure 6 from High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial Open
Models of PI3 kinase-AKT signalling in FGFR driven cell lines.
Supplementary Figure 6 from High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial Open
Models of PI3 kinase-AKT signalling in FGFR driven cell lines.
Data from High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial Open
FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal FGFR2 amplification …